МАС Катрин (CH),БОВЕТТО Лионель Жан Рене (CH),ПУТО Этьенн (CL)
申请号：
RU2014120428/15
公开号：
RU2014120428A
申请日:
2012.10.19
申请国别(地区):
RU
年份:
2015
代理人:
摘要：
1. Micelles whey protein for use in the treatment and / or prophylaxis of disorders associated with increased insulin secretion and / or IGF-1 concentration in the plasma of an infant at risk of developing obesity or diabeta.2. protein micelles whey according to Claim. 1, wherein the disorder is selected from the group consisting of obesity, insulin resistance, metabolic syndrome, glucose intolerance, and type 2 diabetes tipa.3. protein micelles whey according to Claim. 1 or 2, intended for administration to the infant from birth until the age of 36 mesyatsev.4. protein micelle according to claim whey. 1 which represent at least 30% of the protein source mladentsa.5 daily diet. The nutritional composition for infants for use in the treatment and / or prophylaxis of disorders associated with increased insulin secretion and / or IGF-1 concentration in the plasma, wherein the nutritional composition comprises a lactic syvorotki.6 protein micelles. The nutritional composition according to claim. 5, for which the disorder is selected from the group consisting of obesity, insulin resistance, metabolic syndrome, glucose intolerance, and type 2 diabetes tipa.7. The nutritional composition according to claim. 5 or 6, further comprising kazein.8. . The nutritional composition according to claim 7, wherein the whey to casein weight ratio is from 80:20 to 20:80, preferably from 70:30 to 30:70 or from 60:40 to 40: 60.9. The nutritional composition according to claim. 5 or 6, wherein the whey protein micelles are from 80 to 100% of the content of nutritious kompozitsii.10 protein. The nutritional composition according to claim. 5, wherein the protein content is in the range from 1.4 to 3.8 g per 100 kkal.11. Nontherapeutic use pit1. Мицеллы белка молочной сыворотки для применения при лечении и/или профилактике расстройства, связанного с повышением секреции инсулина и/или концентрации IGF-1 в плазме у младенца с риском развития ожирения или диабета.2. Мицеллы белка молочной сыворо
